Tiziana life sciences doses first patient in phase 2a trial of intranasal foralumab in multiple sclerosis

New york, dec. 19, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-spms).   six investigational centers have been recruited for this double-blind, placebo-controlled trial, with up to 18 patients per treatment arm. the primary endpoint of the trial will be the change in microglial activation based on pet scans. clinical evaluations include the expanded disability status scale (edss), qol assessments, and the modified fatigue impact scale (mfis), which assess parameters that are essential to a patient's everyday life. novel immuno-biomarkers will be measured also and assessed for predictive relevance. central review of pet scans and images is an integral component of this study.
TLSA Ratings Summary
TLSA Quant Ranking